Overall, the guidelines recommend PSMA PET imaging during the primary diagnosis/initial staging of the disease for patients with intermediate and high-risk prostate cancer and for those with recurrence after initial treatment [7]. This evidence concerns the gene FOLH1 and prostate carcinoma.